Bioventix BVXP ShareSoc Richmond 6 6 16

100%

838 Views

4 Likes

6th June 2016

Peter Harrison CEO Bioventix (BVXP)
ShareSoc Richmond 6.6.16

A succinct presentation to understand what BVXP do.

• The product
• Revenue streams
• Stickiness of revenue
• Timelines to develop revenue streams
• Barriers to entry
• Threats
• The future

A sense of the culture of the company

The journey of the historic research that led to current products.

The pipeline of future products.

Peter Harrison is a 12% shareholder, Miton 14.5% and other institutional holders

Q&A at 38:55, with questions around possible threats covering:

• Impact of loss of NT proBNP, and replacement of revenues by Troponin
• Technological threats
• Time it’s taken to get Treponin to market
• The future of company
• Personalise medicine
• Collaborations with other organisations

Presentation slides can be viewed here.

Videos from Bioventix

21:17

Bioventix (BVXP) Full Year results June 2016 interview

Length: c 20 mins Peter Harrison, CEO, talks through the latest FY results 30 June 2016 with @tamzinpiworld. He expands on the success of Vitamin D and its future prospects, together with the positive impact of foreign exchange. He goes on to talk about the NT proBNP licence, which comes to an end July 2017, […]

piworld

19th October 2016

445

07:01

Bioventix – BVXP – Company overview

Introduction to Bioventix (BVXP) by Peter Harrison, CEO Length: c. 6 mins Peter Harrison, CEO, tells us what Bioventix does, and discusses the business model. Essentially BVXP develops antibodies for use in different blood testing machines manufactured by the big names: Roche, Siemens, Abbot, etc. He goes into detail about BVXP antibodies types, and why […]

piworld

19th October 2016

265